PROTEOME SCIENCES PLC

Regulatory Filings • Jun 12, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6479H

Proteome Sciences PLC

12 June 2017

Proteome Sciences plc

("Proteome Sciences" or the "Company"

New Registered Address

Proteome Sciences plc (AIM:PRM) is pleased to announce that its corporate headquarters have moved from Cobham to new premises in central London, and the Board has approved that from 12 June 2017 the new registered address will be Hamilton House, Mabledon Place, London, WC1H 9BB.

This office relocation marks the final step in the consolidation of company premises which also saw the integration of all laboratory capabilities in Frankfurt from 1 May 2017.

For further information: Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer                        Tel: +44 (0)1932 865065
Dr Ian Pike, Chief Scientific Officer
Geoff Ellis, Finance Director
finnCap Limited (Nominated Adviser/Broker) Geoff Nash/James Thompson	Tel: +44 (0)20 7220 0500
Tony Quirke (broking) IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Nolan	Tel: +44 (0)20 3053 8671

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAPKNEEFXEEF